C3a receptor antagonist attenuates brain injury after intracerebral hemorrhage

Michal A. Rynkowski, Grace H. Kim, Matthew C. Garrett, Brad Zacharia, Marc L. Otten, Sergei A. Sosunov, Ricardo J. Komotar, Benjamin G. Hassid, Andrew F. Ducruet, John D. Lambris, E. Sander Connolly

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

Neuroprotective therapy targeting the complement cascade may reduce injury associated with intracerebral hemorrhage (ICH). We investigated the role of C3a-receptor antagonist (C3aRA) after ICH in mice. Autologous whole blood was infused into the right striatum of mice that were treated with C3aRA or vehicle, using both a pre- and postinjury dosing regimen. Hematoma volume, brain water content, and inflammatory cell profile were assessed at 72 h post-ICH. Neurologic dysfunction was assessed by evaluating both spatial memory and sensorimotor capacity. Animals pretreated with C3aRA showed significantly improved neurologic function, brain water content, and granulocyte infiltration relative to vehicle-treated animals when assessed at 72 h. There was no significant difference in hemorrhagic/nonhemorrhagic ratio of microglial activation among all groups. Hematoma volumes were also not significantly different between C3aRA-treated and vehicle-treated animals. Administration of C3aRA beginning 6 h postinjury afforded significant amelioration of neurologic dysfunction as well as a reduction in brain water content. Treatment with C3aRA improved neurologic outcome while reducing inflammatory cell infiltration and brain edema formation after experimental ICH in mice. Results of this study suggest that the C3a receptor may be a promising target for therapeutic intervention in hemorrhagic stroke.

Original languageEnglish (US)
Pages (from-to)98-107
Number of pages10
JournalJournal of Cerebral Blood Flow and Metabolism
Volume29
Issue number1
DOIs
StatePublished - Jan 1 2009

Fingerprint

Cerebral Hemorrhage
Brain Injuries
Neurologic Manifestations
Hematoma
Nervous System
Water
Brain
Brain Edema
Granulocytes
Stroke
Wounds and Injuries
Therapeutics

All Science Journal Classification (ASJC) codes

  • Neurology
  • Clinical Neurology
  • Cardiology and Cardiovascular Medicine

Cite this

Rynkowski, M. A., Kim, G. H., Garrett, M. C., Zacharia, B., Otten, M. L., Sosunov, S. A., ... Connolly, E. S. (2009). C3a receptor antagonist attenuates brain injury after intracerebral hemorrhage. Journal of Cerebral Blood Flow and Metabolism, 29(1), 98-107. https://doi.org/10.1038/jcbfm.2008.95
Rynkowski, Michal A. ; Kim, Grace H. ; Garrett, Matthew C. ; Zacharia, Brad ; Otten, Marc L. ; Sosunov, Sergei A. ; Komotar, Ricardo J. ; Hassid, Benjamin G. ; Ducruet, Andrew F. ; Lambris, John D. ; Connolly, E. Sander. / C3a receptor antagonist attenuates brain injury after intracerebral hemorrhage. In: Journal of Cerebral Blood Flow and Metabolism. 2009 ; Vol. 29, No. 1. pp. 98-107.
@article{7e52318b58c34b41970f1183af3e3f22,
title = "C3a receptor antagonist attenuates brain injury after intracerebral hemorrhage",
abstract = "Neuroprotective therapy targeting the complement cascade may reduce injury associated with intracerebral hemorrhage (ICH). We investigated the role of C3a-receptor antagonist (C3aRA) after ICH in mice. Autologous whole blood was infused into the right striatum of mice that were treated with C3aRA or vehicle, using both a pre- and postinjury dosing regimen. Hematoma volume, brain water content, and inflammatory cell profile were assessed at 72 h post-ICH. Neurologic dysfunction was assessed by evaluating both spatial memory and sensorimotor capacity. Animals pretreated with C3aRA showed significantly improved neurologic function, brain water content, and granulocyte infiltration relative to vehicle-treated animals when assessed at 72 h. There was no significant difference in hemorrhagic/nonhemorrhagic ratio of microglial activation among all groups. Hematoma volumes were also not significantly different between C3aRA-treated and vehicle-treated animals. Administration of C3aRA beginning 6 h postinjury afforded significant amelioration of neurologic dysfunction as well as a reduction in brain water content. Treatment with C3aRA improved neurologic outcome while reducing inflammatory cell infiltration and brain edema formation after experimental ICH in mice. Results of this study suggest that the C3a receptor may be a promising target for therapeutic intervention in hemorrhagic stroke.",
author = "Rynkowski, {Michal A.} and Kim, {Grace H.} and Garrett, {Matthew C.} and Brad Zacharia and Otten, {Marc L.} and Sosunov, {Sergei A.} and Komotar, {Ricardo J.} and Hassid, {Benjamin G.} and Ducruet, {Andrew F.} and Lambris, {John D.} and Connolly, {E. Sander}",
year = "2009",
month = "1",
day = "1",
doi = "10.1038/jcbfm.2008.95",
language = "English (US)",
volume = "29",
pages = "98--107",
journal = "Journal of Cerebral Blood Flow and Metabolism",
issn = "0271-678X",
publisher = "Nature Publishing Group",
number = "1",

}

Rynkowski, MA, Kim, GH, Garrett, MC, Zacharia, B, Otten, ML, Sosunov, SA, Komotar, RJ, Hassid, BG, Ducruet, AF, Lambris, JD & Connolly, ES 2009, 'C3a receptor antagonist attenuates brain injury after intracerebral hemorrhage', Journal of Cerebral Blood Flow and Metabolism, vol. 29, no. 1, pp. 98-107. https://doi.org/10.1038/jcbfm.2008.95

C3a receptor antagonist attenuates brain injury after intracerebral hemorrhage. / Rynkowski, Michal A.; Kim, Grace H.; Garrett, Matthew C.; Zacharia, Brad; Otten, Marc L.; Sosunov, Sergei A.; Komotar, Ricardo J.; Hassid, Benjamin G.; Ducruet, Andrew F.; Lambris, John D.; Connolly, E. Sander.

In: Journal of Cerebral Blood Flow and Metabolism, Vol. 29, No. 1, 01.01.2009, p. 98-107.

Research output: Contribution to journalArticle

TY - JOUR

T1 - C3a receptor antagonist attenuates brain injury after intracerebral hemorrhage

AU - Rynkowski, Michal A.

AU - Kim, Grace H.

AU - Garrett, Matthew C.

AU - Zacharia, Brad

AU - Otten, Marc L.

AU - Sosunov, Sergei A.

AU - Komotar, Ricardo J.

AU - Hassid, Benjamin G.

AU - Ducruet, Andrew F.

AU - Lambris, John D.

AU - Connolly, E. Sander

PY - 2009/1/1

Y1 - 2009/1/1

N2 - Neuroprotective therapy targeting the complement cascade may reduce injury associated with intracerebral hemorrhage (ICH). We investigated the role of C3a-receptor antagonist (C3aRA) after ICH in mice. Autologous whole blood was infused into the right striatum of mice that were treated with C3aRA or vehicle, using both a pre- and postinjury dosing regimen. Hematoma volume, brain water content, and inflammatory cell profile were assessed at 72 h post-ICH. Neurologic dysfunction was assessed by evaluating both spatial memory and sensorimotor capacity. Animals pretreated with C3aRA showed significantly improved neurologic function, brain water content, and granulocyte infiltration relative to vehicle-treated animals when assessed at 72 h. There was no significant difference in hemorrhagic/nonhemorrhagic ratio of microglial activation among all groups. Hematoma volumes were also not significantly different between C3aRA-treated and vehicle-treated animals. Administration of C3aRA beginning 6 h postinjury afforded significant amelioration of neurologic dysfunction as well as a reduction in brain water content. Treatment with C3aRA improved neurologic outcome while reducing inflammatory cell infiltration and brain edema formation after experimental ICH in mice. Results of this study suggest that the C3a receptor may be a promising target for therapeutic intervention in hemorrhagic stroke.

AB - Neuroprotective therapy targeting the complement cascade may reduce injury associated with intracerebral hemorrhage (ICH). We investigated the role of C3a-receptor antagonist (C3aRA) after ICH in mice. Autologous whole blood was infused into the right striatum of mice that were treated with C3aRA or vehicle, using both a pre- and postinjury dosing regimen. Hematoma volume, brain water content, and inflammatory cell profile were assessed at 72 h post-ICH. Neurologic dysfunction was assessed by evaluating both spatial memory and sensorimotor capacity. Animals pretreated with C3aRA showed significantly improved neurologic function, brain water content, and granulocyte infiltration relative to vehicle-treated animals when assessed at 72 h. There was no significant difference in hemorrhagic/nonhemorrhagic ratio of microglial activation among all groups. Hematoma volumes were also not significantly different between C3aRA-treated and vehicle-treated animals. Administration of C3aRA beginning 6 h postinjury afforded significant amelioration of neurologic dysfunction as well as a reduction in brain water content. Treatment with C3aRA improved neurologic outcome while reducing inflammatory cell infiltration and brain edema formation after experimental ICH in mice. Results of this study suggest that the C3a receptor may be a promising target for therapeutic intervention in hemorrhagic stroke.

UR - http://www.scopus.com/inward/record.url?scp=58149168996&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58149168996&partnerID=8YFLogxK

U2 - 10.1038/jcbfm.2008.95

DO - 10.1038/jcbfm.2008.95

M3 - Article

C2 - 18728680

AN - SCOPUS:58149168996

VL - 29

SP - 98

EP - 107

JO - Journal of Cerebral Blood Flow and Metabolism

JF - Journal of Cerebral Blood Flow and Metabolism

SN - 0271-678X

IS - 1

ER -